Sobieszczyk, Magdalena E MD, MPH*; Xu, Guozhen BA†; Goodman, Krista MS†; Lucy, Debbie MS†; Koblin, Beryl A PhD†
A safe and efficacious HIV vaccine is one of the most important priorities of AIDS prevention research. To ensure that the vaccine is applicable across a variety of populations, HIV vaccine trial participants need to reflect the demographics of the epidemic.
In the United States, African Americans and Latinos have experienced a disproportionate burden of HIV infection. The HIV case rate in 2006 was 29.3 per 100,000 among Latinos and 83.7 per 100,000 among African Americans compared with 11.5 per 100,000 among whites.1 New York City has the largest number of AIDS cases and the highest AIDS case rate in the United States. In 2007, 31.5% and 50.4% of the new AIDS diagnoses in New York City were among Latinos and African Americans, respectively.2 Therefore, inclusion of individuals from these communities in HIV vaccine trials is greatly needed.
Historically, Latinos and African Americans have been underrepresented in HIV vaccine clinical trials. For example, in the VaxGen phase III HIV vaccine efficacy trial conducted among 5108 men and 309 women, only 6% of enrollees were African American and 7% Latino, making it difficult to interpret subgroup analyses of these populations.3 Racial/ethnic minority participants represented only 17% of the overall enrollment in National Institute of Allergy and Infectious Diseases-funded network HIV vaccine trials from 1988 to 2004. An encouraging trend was noted as minority participation increased to 27% in 2004, mostly due to an increase in African American participation; Latinos, however, comprised only 4% of study participants in 2004.4
Underrepresentation of men or women from African American and Latino communities may have implications for generalizability of the clinical trial results to these populations. Furthermore, the acceptance of HIV vaccines by communities will likely be influenced by whether or not those communities participated in the clinical research. From a biologic standpoint, race or ethnicity may influence responses to vaccines, given variations in human leukocyte antigen or immune responses.4-7 Therefore, effective strategies are urgently needed to increase participation of minorities in HIV vaccine research.
Enrollment in HIV vaccine trials involves a process starting with community education and information gathering by the potential volunteer to help make an informed decision about participation and by the research team to help determine eligibility. The process continues with obtaining a medical history, conducting a physical examination, collecting specimens, and signing of the final consent to enroll. In this article, several questions that are relevant to developing strategies to engage African Americans and Latinos in vaccine trials are addressed. First, what is the success in reaching and engaging African Americans and Latinos in initial discussions about vaccine trials? Is it possible to retain them through the screening process to determine eligibility, or are there are any differences by race/ethnicity in the proportion of volunteers who fall out in the process? Is it easier to reach and enroll high-risk rather than low-risk individuals? Are particular recruitment methods more effective in reaching and retaining minorities? To address these questions, we report the experience of 2 sites with screening and enrolling volunteers into phase 1 and 2 vaccine trials in New York City. To our knowledge, this is the first study to examine the details of the screening and enrollment process into HIV vaccine trials by race/ethnicity.
Location and Study Population
From October 2002 to April 2006, men and women 18-50 years old who were HIV antibody negative were recruited into National Institutes of Health (NIH)-sponsored preventive HIV vaccine trials at 2 project ACHIEVE research sites in New York City: 1 located in the South Bronx section of New York City, a predominantly African American and Latino community, and 1 in lower Manhattan at Union Square, a predominantly white neighborhood. Project ACHIEVE is a part of the Laboratory of Infectious Disease Prevention of the New York Blood Center. Project ACHIEVE is funded by the NIH HIV Vaccine Trials Network (HVTN).
Volunteers were recruited through a variety of approaches including: advertisements in gay publications and local newspapers; posters in public places (universities, community groups); outreach (community health fairs, bars, and clubs, on the street); and referrals from study participants and staff. Data on the recruitment sources for every participant entering the screening process were collected.
Individuals were enrolled into phase 1 and phase 2 studies based on medical and behavioral eligibility. Men and women were eligible for phase 2 studies if they were at high risk defined as having ≥1 risk factor over the previous 6 months: (1) high-risk women (HRW): unprotected vaginal or anal intercourse with a man known to be HIV infected; unprotected vaginal or anal intercourse with a man who uses injection drugs; exchanged sex for money, drugs, services, or gifts; used crack cocaine at least 3 times; (2) high-risk men: unprotected anal intercourse with another man and/or anal intercourse with 2 or more male sexual partners. Men in a monogamous relationship with an HIV-seronegative partner for >1 year were not high risk. Individuals at low risk for HIV were eligible for phase 1 studies by the absence of high-risk factors.
Medical eligibility criteria differed for phase 1 and phase 2 studies and were stricter for the former. Individuals were eligible to enroll if they had normal medical histories, laboratory evaluations, and physical examinations; were willing to provide written informed consent and comply with study procedures; and met behavioral criteria outlined above.
The number of available phase 1 and phase 2 trials and number of participants enrolled at the 2 New York study sites varied during the study period: in 2002, 12 participants enrolled into 2 phase 1 trials; in 2003, 4 participants enrolled into 1 phase 1 trial; in 2004, 22 participants enrolled into 4 phase 1 trials; in 2005, 5 and 54 participants enrolled into 3 phase 1 and 1 phase 2 trials, respectively; and from January to April 2006, 12 participants enrolled into 2 phase 1 and 17 participants enrolled into 1 phase 2 trial.
Prescreening and Screening Procedures
The screening process consisted of 6 stages. The first stage was a telephone interview using a prescreen questionnaire containing 28 questions about participant's demographic, medical, and behavioral risk. Participants who were preliminarily eligible based on the questionnaire were invited to come to one of our research sites for the second stage, a one-on-one vaccine education and discussion visit. The educational materials and visual aids were standardized across both sites. If interested in the study, the individual proceeded to the third stage, reviewing and signing of a screening informed consent form. The fourth stage was a medical history screening, and the fifth stage was a physical examination and a blood draw. If the individual remained interested in participating and met study eligibility criteria, he/she proceeded to the final stage, enrollment, defined as administration of the first study injection. The speed (and number of visits) by which participants progressed through the stages was determined by the participant willingness to engage, time availability, staff assessment, and eligibility to progress to the next stage. Thus some stages may have occurred at the same visit-eg, a physical examination and blood draw (stage 5) may have occurred at the same visit as the medical screening (stage 4) if the participant passed the medical screening and was willing to have the other procedures completed at that time. On the other hand, informed consent and protocol-specific education (stage 3) may have occurred over more than 1 visit if desired by the participant. Potential participants could proceed or drop out at any 1 of the 6 stages. There was significant diversity among the clinicians and counselors conducting the visits; women, Latinos, and African Americans were well represented.
The main outcome measure was successful completion of the screening process and enrollment into a vaccine trial. A total of 2251 prescreen questionnaires were completed between October 2002 and April 2006. A separate log was kept to record the completion of the stages from prescreening to enrollment. Questionnaire data were merged to the log by first and last initials and date of birth (merged data set n = 2533). After reconciling the records and excluding subjects who had only a prescreen questionnaire (n = 450) or who were listed in the log but missing the prescreen questionnaire (n = 248), a merged database of 1835 individuals with complete data was created. There were 269 duplicate records which were reviewed and handled as follows: for individuals who prescreened more than once (n = 89), the earlier prescreen date was chosen and the other record was deleted; duplicate entries were reviewed and complete ones retained (n = 28); participants who screened at both of our research sites were deleted from the database. The final merged database of 1683 records was used for analysis. There was no difference in the ethnic/racial distribution (proportion of African Americans and Latinos) of individuals with only prescreen questionnaires compared with prescreeners with complete data. Including individuals with missing data in the analysis did not significantly change the proportion of African American and Latino completing the prescreen questionnaire stage (data not shown).
Categorical variables were compared using χ2 or Fisher exact test. Multivariate logistic models were used to describe the independent predictors of enrollment. Variables included in the final model were those significantly (P < 0.05) associated with successful enrollment on univariate analysis.
Characteristics of Screened and Enrolled Participants
Figure 1 outlines the stages of screening and number of participants who completed each stage of the screening process. Of 1683 individuals who completed the prescreen questionnaire over the telephone, 126 (7.5%) proceeded to the final stage of enrollment.
The demographic characteristics of individuals who completed the prescreen questionnaire and their disposition in the screening process are summarized in Table 1. The largest groups of individuals who contacted the site and completed the questionnaire were white (33.7%) and male (66.7%) and were in the 36-45 age group (36.5%). The majority of initial contacts were generated from referrals, street outreach, and advertisements. Almost a quarter of the individuals initiating the screening process reported prior medical conditions which would exclude them from participating in a trial, and 91% had undergone HIV testing in the past.
Overall, 31.3% of the volunteers who completed a prescreen questionnaire were African American, and 25.0% were Latino (Table 1). Individuals from ethnic/racial minorities were successfully retained through the 6 stages of screening: 33.3% of the enrollees were African American, and 23.6% were Latino.
Behavioral risk criteria differed among individuals who proceeded through the screening stages (Table 1). Low-risk men (LRM) were more likely than others to complete every stage of screening, with the notable exception of the enrollment visit. Although over one third of individuals completing vaccine education through physical exam visit were LRM, there were only 16% of them among enrollees. HRW, on the other hand, once they entered the screening process, were very likely to complete it and proceed to an enrollment visit; a little over 9% of prescreeners were HRW, but they constituted almost a quarter of total enrollments. It should be noted, however, that the number of protocols open to enrollment for low-risk vs. high-risk individuals varied during this period; for example, in 2003, only 1 phase 1 (4 participants enrolled) and no phase 2 trials were available, whereas in 2005, the sites were screening and recruiting participants for 3 phase 1 and 1 phase 2 trials (9 and 54 participants enrolled into phase 1 and phase 2 trials, respectively) (Table 1). This may account for differences in the screen to enrollment ratios among LRM and HRW.
Multivariate analyses of factors associated with proceeding to an enrollment visit are shown in Table 2. Older participants, high-risk men, and HRW were more likely to proceed to enrollment on multivariate analysis. Race/ethnicity was not associated with enrollment. The use of flyers/postcards and website/other strategies were associated with successful enrollment.
Table 3 presents the comparison of high-risk (phase 2) and low-risk (phase 1) individuals at each stage of screening. Although women were more likely to prescreen for phase 1 trials, the proportion of women participating in phase 1 vs. phase 2 trials was not significantly different of all subsequent stages of the screening process (Table 3). Overall, the largest proportion of participants at every stage of phase 1 screening was African American. We were also more successful at recruiting, screening, and enrolling African Americans into phase 1 compared with phase 2 vaccine studies: for example, 48.9% in phase 1 vs. 23.0% enrolled in phase 2 studies (P = 0.006). We were less successful, however, enrolling low-risk compared with high-risk Latinos: only 12.8% of individuals enrolling into phase 1 were Latinos compared with 31.1% enrolling into phase 2 studies (P = 0.006).
Effective recruitment methods differed among participants prescreening for phase 1 vs. phase 2 study (Table 3). Among our phase 1 prescreeners and individuals completing every stage of the process, advertisements, for example, seemed most effective (26.3% of phase 1 prescreens), whereas referrals and outreach were more successful in bringing in phase 2 individuals. However, the percents enrolled by different recruitment strategies were not significantly different. No significant differences were identified between effective sources of recruitment for men, women, and ethnic minority groups enrolling in the vaccine studies (data not shown). Although ethnically specific or Spanish language print media were not targeted, the recruitment team engaging in direct street and bar outreach was composed of outreach workers from diverse communities.
Reasons for Screen Failure
The proportion not completing a vaccine education visit was the highest among Latinos (65.6%) and the group of Asian/Pacific Islander, native American/American Indian, and others self-identified as “other” (66.7%) (Table 4). African Americans were the most likely to fail completing the medical screening visit.
Among participants who did not complete enrollment, 24.8% were ineligible for medical reasons, 16.1% did not meet behavioral criteria, 28.0% were lost to follow-up or did not show, 26.9% refused participation, and 4.2% did not enroll for other reasons (age, waitlisted, referred to the other site) (Table 5). Medical eligibility criteria for enrollment into phase 1 studies were considerably stricter than for phase 2 trials, and failure to enroll for medical reasons was more common for phase 1 compared with phase 2 studies (27.2% vs. 19.6%) (Table 5 and data not shown).
The reason for not enrolling differed among volunteers from ethnic/racial groups. Overall, the percent who were lost to follow-up or no shows were higher among Latinos and African Americans than whites (32.1% and 29.3% vs. 23.9%, P < 0.0001), whereas active refusal to participate was the least common reason for dropping out (20.0% and 15.0% for Latinos and African Americans, respectively, compared with 40.1% for whites, P < 0.0001).
For phase 1 trials for which we were least successful enrolling Latinos, the most common reason for failure to enroll this population was loss to follow-up (28.8%) followed by medical ineligibility (26.6%) (Table 5). Of note, loss to follow-up was higher among Latinos than whites screening for both phase 1 (28.8% vs. 20.6%) and phase 2 trials (37.9% vs. 29.6%). Among African Americans, screening for phase 1 and phase 2 studies, medical ineligibility, and loss to follow-up were the most common reasons for not enrolling (Table 5). The percent refusing to participate was lower among African Americans and Latinos for both phase 1 and 2 trials.
The experience from 2 research sites in New York demonstrates that it is possible to recruit, prescreen, and retain in the screening process African American and Latino volunteers. Among participants enrolled into vaccine trials at our site, 33.3% were African American and 23.6% were Latino. There were no significant differences in the percentage of Latinos or African Americans who prescreened and subsequently enrolled in vaccine studies at 2 New York sites; we noted, however, that the sites were more successful enrolling Latinos into phase 2 studies and African Americans into phase 1 studies. Potential reasons for this discrepancy may include use of specific recruitment strategies, such as targeted street outreach in Latino communities, which tapped into high-risk subgroups, or differences in the communities' perception of phase 1 and phase 2 trials. It is possible that Latinos are less willing to enroll into early phase 1 trials rather than efficacy trials. Although active refusal to follow-up was lower among African Americans and Latinos, loss to follow-up during the screening process was more common in both groups compared with whites, and this may represent a form of “passive refusal.”
In 1994, the National Institutes of mandated better representation of minorities in NIH-sponsored clinical research. Since then, however, enrollment of minorities continues to be a challenge.8,9 Previous work has attempted to elucidate barriers to enrollment in HIV vaccine trials. Factors such as concerns about safety of the vaccines, social risks as a result of participation or testing HIV antibody positive after receiving an HIV vaccine, and the burden of study follow-up have been cited as potential barriers to participation in the high-risk populations.10-21 Compounding these barriers is the history of abuses and disenfranchisement of minority participants in medical research. It has been shown that the primary reason for reluctance to participate in HIV vaccine trials among Spanish-speaking Latinos was mistrust and fear of government and government-sponsored HIV/AIDS medical research.22 African Americans and English-speaking Latinos in HIV-related research have cited similar concerns23-26; among African Americans, mistrust was the strongest predictor of unwillingness to participate in HIV research.27 Other potential barriers to participation may be due to limited access to research studies in addition to unwillingness to enroll13,28,29 and that individuals from ethnic minorities may be less likely to be informed about clinical trials than nonminority participants. Wendler et al,28 for example, assessed whether minority groups invited to participate in health research were less likely to consent to participate than nonminority individuals. The authors found only small differences in consent rates by race or ethnicity but noted substantially lower numbers of individuals invited to participate in research, HIV studies in particular. Lack of knowledge of HIV vaccines may be an important barrier to participation among these groups. In a national telephone survey, 53% of Latinos and 37% of African Americans had read or heard anything about HIV vaccine research in the prior 12 months. A higher proportion of Latinos (27%) and African Americans (47%) compared with the general population or high-risk men who have sex with men (18% and 13%, respectively) thought a vaccine already exists but is being kept a secret.30
Misconceptions about HIV vaccine research exist, but these results suggest that, once given the opportunity to participate, minority groups are equally likely to enroll into vaccine studies. It remains to be seen whether these findings are generalizable to other sites within the HVTN network. The reasons for our success may be due to factors such as location of the 2 research clinics in culturally and ethnically diverse neighborhoods in South Bronx and lower Manhattan; free standing office space physically detached from a hospital or medical clinic thereby minimizing any potential stigma of participating in a research study; long established history in the community with a strong community education; the screening process and vaccine education carried out over several visits; and our diverse and bilingual staff reflecting the target populations. All of these factors can contribute to creating an environment that facilitates communication and trust between participants and study staff.
Limitations of this study include the retrospective design and the fact that it was limited to only 2 sites in 1 city. Although enrollment rates of Latinos and African Americans at our sites are higher than what has been previously reported for all study sites conducting phase 1 or 2 trials within the HVTN,4 much still remains to be done. It seems that to raise the overall participation of Latinos and African Americans in vaccine trials at these 2 sites, a crucial step is to increase the initial pool of individuals prescreening for studies. Targeted strategies for reaching out to individuals, such as low-risk Latinos and high-risk African Americans, need to be developed. To ensure successful inclusion of minority groups, it is crucial that efforts focus on substantive community education to raise awareness, foster an environment of trust, dispel misconceptions, and lay the foundation for culturally relevant and culturally sensitive recruitment strategies. This could be accomplished through building partnerships with community-based minority organizations to strengthen community engagement with researchers. Through these collaborations, we can make sure that information about HIV vaccine research is disseminated, our goals are clearly communicated, and trust is firmly established.
Recent developments in the HIV vaccine field may pose an even greater challenge to accomplishing this goal. In September 2007, based on the Data and Safety Monitoring Board review of the phase IIB, test of concept, efficacy trial in the Americas (the STEP study, HVTN 502/Merck 023), vaccinations in this trial were stopped as statistical criteria for futility had been met.31 Data released in November 2007 also raised the question of whether there was an increased risk of HIV acquisition conferred by the vaccine in persons with preexisting immunity to adenovirus type 5.32 In wake of these developments, potential for misconceptions about HIV vaccine research may grow. It is therefore more important than ever to ensure that researchers engage members of the community and its organizations in open dialogue, dissemination of accurate information, and that sight should not be lost of the need to develop an effective preventive vaccine. As we move the field forward and embark on other vaccine trials, it is imperative that we ensure equitable representation of groups most affected by this epidemic and in greatest need of preventive interventions.
We gratefully acknowledge the contributions of the recruitment and retention team, counselors and clinicians at the Bronx and Union Square sites, and the help and dedication of study participants.
1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA
3. Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis
4. Djomand G, Katzman J, di Tommaso D, et al. Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep
5. Montefiori DC, Altfeld M, Lee PK, et al. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol
6. Gilbert PB, DeGruttola VG, Hudgens MG, et al. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis
7. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes
. 2004;11(Suppl 3):161A-169A.
8. Gifford AL, Cunningham WE, Heslin KC, et al. Participation in research and access to experimental treatments by HIV-infected patients. N Engl J Med
9. Oddone EZ, Olsen MK, Lindquist JH, et al. Enrollment in clinical trials according to patients race: experience from the VA Cooperative Studies Program (1975-2000). Control Clin Trials
10. Koblin BA, Avrett S, Taylor PE, et al. Willingness to participate in HIV-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol
11. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS
12. Koblin BA, Holte S, Lenderking B, et al. Readiness for HIV vaccine trials: changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. The HIVNET Vaccine Preparedness Study Protocol Team. J Acquir Immune Defic Syndr
13. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS
14. Buchbinder SP, Metch B, Holte SE, et al. Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation. J Acquir Immune Defic Syndr
15. O'Connell JM, Hogg RS, Chan K, et al. Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial. J Acquir Immune Defic Syndr
16. Hays RB, Kegeles SM. Factors related to the willingness of young gay men to participate in preventive HIV vaccine trials. J Acquir Immune Defic Syndr Hum Retrovirol
17. Sheon AR, Wagner L, McElrath MJ, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol
18. Vlahov D, Astemborski J, Solomon L, et al. Interest in HIV vaccines among injection drug users in Baltimore, Maryland. AIDS Res Hum Retroviruses
. 1994;10(Suppl 2):S265-S268.
19. Newman PA, Duan N, Kakinami L, et al. What can HIV vaccine trials teach us about future HIV vaccine dissemination? Vaccine
20. Newman PA, Duan N, Lee SJ, et al. Willingness to participate in HIV vaccine trials: the impact of trial attributes. Prev Med
21. Frew PM, Crosby RA, Salazar LF, et al. Acceptance of a potential HIV/AIDS vaccine among minority women. J Natl Med Assoc
22. Brooks RA, Newman PA, Duan N, et al. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care
23. Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. J Acquir Immune Defic Syndr
24. Newman PA, Duan N, Rudy ET, et al. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come? AIDS Patient Care STDS
25. Strauss RP, Sengupta S, Kegeles S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr
26. Newman PA, Duan N, Rudy ET, et al. HIV risk and prevention in a post-vaccine context. Vaccine
27. Sengupta S, Strauss RP, DeVellis R, et al. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr
28. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in health research? PLoS Med
29. Mandelblatt J, Kaufman E, Sheppard VB, et al. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials? Prev Med
30. Allen MA, Liang TS, La Salvia T, et al. Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. J Acquir Immune Defic Syndr
31. Merck. Vaccination and enrollment are discontinued in Phase II trials of Merck's investigational HIV vaccine candidate: Interim analysis of STEP study shows vaccine was not effective [news release]. Whitehouse Station, NJ: Merck; September 21, 2007.
32. Merck. Data from STEP Study Presented at Open Scientific Session Confirm Merck's Investigational HIV Vaccine was not Effective [press release] Research & Development News, Whitehouse Station, NJ: Merck & Co, Inc; November 7, 2007.
© 2009 Lippincott Williams & Wilkins, Inc.